• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中间型地中海贫血的最终身高和内分泌功能

Final height and endocrine function in thalassaemia intermedia.

作者信息

De Sanctis V, Tangerini A, Testa M R, Lauriola A L, Gamberini M R, Cavallini A R, Rigolin F

机构信息

Department of Paediatrics and Adolescent Medicine, Arcispedale S. Anna, Ferrara, Italy.

出版信息

J Pediatr Endocrinol Metab. 1998;11 Suppl 3:965-71.

PMID:10091174
Abstract

We present data of a detailed study of endocrine function in 50 patients (21 males, 29 females) with thalassaemia intermedia, 15-46 years old (mean age 28.7 yr), with raised serum ferritin levels (mean 1540 micrograms/l). Mean haemoglobin concentration was 8.1 g/dl. Half of them had had more than 50 transfusions in their life and had received irregular intramuscular or subcutaneous chelation therapy. Delayed puberty was one of the most frequent (36%) clinical endocrine abnormalities found in our patients. Primary amenorrhea was observed in two patients and secondary amenorrhea in four patients. Two males, aged 19 and 36 years, had hypogonadism. A poor response to GnRH, found in three females and in both males tested, suggested that pituitary dysfunction was wholly or partially responsible for hypogonadism. Gonadal function was normal in all patients studied. Glucose intolerance and primary hypothyroidism were less frequent (24 and 5.7%, respectively) and milder than in thalassaemia major patients. Two patients had low T3 and T4 and normal basal and stimulated response of TSH to TRH. This condition has been found in euthyroid sick syndrome and it is likely that it represents an adaptive response by the body to minimize catabolism when undergoing major stress. As a consequence, we believe that periodic endocrine evaluation should be carried out in subjects with beta-thalassaemia intermedia, particularly in those over 14 years old, in order to detect and to treat endocrine dysfunction.

摘要

我们展示了对50例中间型地中海贫血患者(21例男性,29例女性)内分泌功能的详细研究数据,这些患者年龄在15至46岁之间(平均年龄28.7岁),血清铁蛋白水平升高(平均1540微克/升)。平均血红蛋白浓度为8.1克/分升。其中一半患者一生中接受过超过50次输血,并接受过不规律的肌肉注射或皮下螯合治疗。青春期延迟是我们患者中最常见的临床内分泌异常之一(36%)。两名患者出现原发性闭经,四名患者出现继发性闭经。两名年龄分别为19岁和36岁的男性患有性腺功能减退。在三名女性和两名接受检测的男性中发现对促性腺激素释放激素(GnRH)反应不佳,提示垂体功能障碍完全或部分导致了性腺功能减退。所有研究患者的性腺功能均正常。葡萄糖耐量异常和原发性甲状腺功能减退较重型地中海贫血患者少见(分别为24%和5.7%)且程度较轻。两名患者T3和T4水平低,促甲状腺激素(TSH)对促甲状腺激素释放激素(TRH)的基础和刺激反应正常。这种情况在正常甲状腺病态综合征中已被发现,很可能是身体在遭受重大应激时为尽量减少分解代谢而做出的适应性反应。因此,我们认为对于中间型β地中海贫血患者,尤其是14岁以上的患者,应定期进行内分泌评估,以便检测和治疗内分泌功能障碍。

相似文献

1
Final height and endocrine function in thalassaemia intermedia.中间型地中海贫血的最终身高和内分泌功能
J Pediatr Endocrinol Metab. 1998;11 Suppl 3:965-71.
2
Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).重型地中海贫血患者内分泌并发症及身材矮小的患病率:地中海贫血国际联合会(TIF)的一项多中心研究
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:249-55.
3
Endocrine complications in patients with Thalassaemia Major.重型地中海贫血患者的内分泌并发症
Pediatr Endocrinol Rev. 2007 Dec;5(2):642-8.
4
[Growth and endocrine function in major thalassemia].[重型地中海贫血的生长与内分泌功能]
Arch Fr Pediatr. 1993 Oct;50(8):657-63.
5
Growth and management of short stature in thalassaemia major.重型地中海贫血患儿身材矮小的生长与管理
J Pediatr Endocrinol Metab. 1998;11 Suppl 3:835-44.
6
Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.性腺功能减退、糖尿病、甲状腺功能减退、甲状旁腺功能减退:1980年至2007年在费拉拉中心随访的重型地中海贫血患者中与铁过载及螯合疗法相关的发病率和患病率
Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:158-69.
7
Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.重型β地中海贫血中生长激素和促性腺激素分泌所致生长及青春期发育障碍的患病率
Arch Iran Med. 2006 Oct;9(4):329-34.
8
Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.血清铁蛋白水平作为重型地中海贫血患者生长发育受损和青春期延迟的预测指标。
Eur J Haematol. 2005 Feb;74(2):93-100. doi: 10.1111/j.1600-0609.2004.00371.x.
9
Low bone mineral density in adolescents with beta-thalassemia.β地中海贫血青少年的低骨矿物质密度
Ann N Y Acad Sci. 2005;1054:462-6. doi: 10.1196/annals.1345.063.
10
Assessment of thyroid functions and its role in body growth in thalassemia major.重型地中海贫血患者甲状腺功能评估及其在身体生长中的作用。
Indian Pediatr. 1995 Feb;32(2):213-9.

引用本文的文献

1
In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbbth3/+) mice.体内沉默肠道 DMT1 可减轻中间型β-地中海贫血(Hbbth3/+)小鼠的铁负荷。
Blood Adv. 2024 Nov 26;8(22):5753-5765. doi: 10.1182/bloodadvances.2024013333.
2
A retrospective study of glucose homeostasis, insulin secretion, sensitivity/resistance in non- transfusion-dependent β-thalassemia patients (NTD- β Thal): reduced β-cell secretion rather than insulin resistance seems to be the dominant defect for glucose dysregulation (GD).一项关于非输血依赖型β地中海贫血患者(NTD-βThal)葡萄糖稳态、胰岛素分泌、敏感性/抵抗性的回顾性研究:对于葡萄糖调节异常(GD),似乎β细胞分泌减少而不是胰岛素抵抗是占主导地位的缺陷。
Acta Biomed. 2023 Dec 5;94(6):e2023262. doi: 10.23750/abm.v94i6.15001.
3
The Link of Pancreatic Iron with Glucose Metabolism and Cardiac Iron in Thalassemia Intermedia: A Large, Multicenter Observational Study.中间型地中海贫血患者胰腺铁与葡萄糖代谢及心脏铁的关联:一项大型多中心观察性研究
J Clin Med. 2021 Nov 26;10(23):5561. doi: 10.3390/jcm10235561.
4
Marital status and paternity in patients with Transfusion- Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries.依赖输血的地中海贫血(TDT)和非依赖输血的地中海贫血(NTDT)患者的婚姻状况和亲子关系:一项国际地中海贫血研究与治疗协作组(ICET)在不同国家开展的调查。
Acta Biomed. 2019 Sep 6;90(3):225-237. doi: 10.23750/abm.v90i3.8586.
5
Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.中间型β地中海贫血患者的最终身高及内分泌并发症:我们在未输血与少量输血患者中的经验及与肝脏铁含量的相关性
Mediterr J Hematol Infect Dis. 2019 May 1;11(1):e2019026. doi: 10.4084/MJHID.2019.026. eCollection 2019.
6
An ICET- A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report.地中海贫血重型和中间型患者甲状旁腺功能减退症的调查:初步报告
Acta Biomed. 2018 Jan 16;88(4):435-444. doi: 10.23750/abm.v88i4.6837.
7
Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis.接受去铁胺治疗的伊朗重型地中海贫血患者的听力损失:一项系统评价和荟萃分析。
Caspian J Intern Med. 2017 Fall;8(4):239-249. doi: 10.22088/cjim.8.4.239.
8
Late-onset Hemochromatosis: Co-inheritance of β-thalassemia and Hereditary Hemochromatosis in a Chinese Family: A Case Report and Epidemiological Analysis of Diverse Populations.迟发性血色素沉着症:一个中国家庭中β地中海贫血与遗传性血色素沉着症的共同遗传:病例报告及不同人群的流行病学分析
Intern Med. 2018 Dec 1;57(23):3433-3438. doi: 10.2169/internalmedicine.8628-16. Epub 2017 Sep 25.
9
Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis study.伊朗重型地中海贫血患者中糖尿病、空腹血糖受损及糖耐量受损的患病率:一项荟萃分析研究。
Caspian J Intern Med. 2017 Winter;8(1):1-15.
10
Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment.中间型β地中海贫血的内分泌和骨骼并发症:当前的认识与治疗
Biomed Res Int. 2015;2015:813098. doi: 10.1155/2015/813098. Epub 2015 Mar 5.